title: Parkinson disease: PD biomarkers-use of α-synuclein reaches new levels.
abstract: Biomarker development is important to the therapeutic imperative for neurodegenerative diseases, as biomarkers hold transformative promise for the design and conduct of clinical trials and, ultimately, for medical management of these diseases. Some of this promise is now being realized in Alzheimer disease, and progress in Parkinson disease is accelerating.
authors.affiliation: Department of Pathology, University of Washington, 300 9th Avenue, Seattle, WA 98104, USA. tmontine@u.washington.edu.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Montine
mesh_terms: D000544:Alzheimer Disease / Q000175:diagnosis / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid / Q000378:metabolism; D015415:Biomarkers / Q000097:blood*; D006801:Humans; D019636:Neurodegenerative Diseases / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000378:metabolism; D010300:Parkinson Disease / Q000175:diagnosis* / Q000378:metabolism; D051844:alpha-Synuclein / Q000097:blood*; D016875:tau Proteins / Q000134:cerebrospinal fluid / Q000378:metabolism
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D051844:alpha-Synuclein; D016875:tau Proteins